Jazz Pharmaceuticals PLC（JAZZ）股票分析JAZZJazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Jazz Pharmaceuticals appears to be a good buy right now due to its current price of $214, which is significantly below the average analyst price target of $313. Additionally, the company has shown a strong gross margin of 76.30% in Q2 2026, indicating solid profitability. The main risk is the negative sentiment reflected in the RSI of 44.384, suggesting potential short-term weakness, but the long-term outlook remains positive.

21 analysts cover JAZZ: 16 rate it Buy, 5 Hold and 0 Sell. The average price target is 218.92.